Across TCGA pan-cancer cohorts, IGKV1-32 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of IGKV1-32’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where IGKV1-32 RNA is repressed in tumor relative to normal tissue. In most cancer types IGKV1-32 is over-expressed in tumor, although a few such as STAD and BRCA show the opposite, repressed pattern.
STAD, LUAD, and BRCA are the cancer types where IGKV1-32 tumor–normal differential expression is most reproducible.